CELGENE CORPORATION

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

First-in-human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of CC-90001

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: CC-90001
Drug: Placebo

First Posted Date: 2014-04-10

Last Posted Date: 2014-10-15

Lead Sponsor: Celgene Corporation

Target Recruit Count: 96

Registration Number: NCT02110420

Locations: 🇺🇸
PPD Development, LP, Austin, Texas, United States

Phase 2 Study With Abraxane (Nab®Paclitaxel) in Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Neoplasms

Interventions: Drug: ABI-007

First Posted Date: 2014-04-03

Last Posted Date: 2020-04-21

Lead Sponsor: Celgene

Target Recruit Count: 41

Registration Number: NCT02103062

Locations: 🇫🇷
Centre Oscar Lambret, Dept. de Cancerologie Digestive et Urologique, Lille 59, France
🇫🇷
Institut Gustave Roussy Hematologie, Villejuif, France
🇫🇷
Institut Curie, Saint-Cloud, France

and more 3 locations

Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma in Relapse
Refractory Multiple Myeloma
Multiple Myeloma

Interventions: Drug: pomalidomide
Drug: marizomib
Drug: low-dose dexamethasone

First Posted Date: 2014-04-03

Last Posted Date: 2017-11-22

Lead Sponsor: Celgene

Target Recruit Count: 38

Registration Number: NCT02103335

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
Karmanos Cancer Center, Detroit, Michigan, United States

and more 3 locations

Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis

Phase 2

Completed

Conditions: Eosinophilic Esophagitis

Interventions: Drug: RPC4046
Drug: Placebo

First Posted Date: 2014-03-28

Last Posted Date: 2017-05-09

Lead Sponsor: Celgene

Target Recruit Count: 100

Registration Number: NCT02098473

Locations: 🇺🇸
West Michigan Clinical Research Center Gastroenterology Associates of Western Michigan, Wyoming, Michigan, United States
🇺🇸
Metropolitan Gastroenterology Group Chevy Chase Clinical Research, Chevy Chase, Maryland, United States
🇺🇸
GI Associates and Endoscopy Center-GI Clinical Research Department, Flowood, Mississippi, United States

and more 27 locations

Health Outcomes of Recently Diagnosed Myelodysplastic Syndrome (MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Depending on Treatment Strategy (Wait and See, Support, Active Treatment)

Completed

Conditions: Leukemia, Myelomonocytic, Chronic
Myelodysplastic Syndrome

Interventions: Other: Either Wait and See, or Supportive Treatment, or Active Treatment at physician discretion

First Posted Date: 2014-03-13

Last Posted Date: 2020-01-27

Lead Sponsor: Celgene

Target Recruit Count: 503

Registration Number: NCT02085798

Locations: 🇪🇸
Hospital Universitario Txagorritxu, Vitoria, Alava, Spain
🇪🇸
Hospital Universitari Germans Trias I Pujol, Badalona, Barcelona, Spain
🇪🇸
Hospital Punta de Europa, Algeciras, Cádiz, Spain

and more 47 locations

Study to Evaluate Pharmacokinetics of Single Oral Doses of Formulated and Non-Formulated CC-122, and Food Effect Study

Phase 1

Completed

Conditions: Clinical Pharmacology, Healthy Male Volunteer Study

Interventions: Drug: CC-122

First Posted Date: 2014-01-30

Last Posted Date: 2019-11-12

Lead Sponsor: Celgene

Target Recruit Count: 18

Registration Number: NCT02049528

Locations: 🇺🇸
Covance Clinical Development Services, Daytona Beach, Florida, United States

Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis

Phase 3

Completed

Conditions: Relapsing Multiple Sclerosis

Interventions: Drug: Ozanimod placebo
Drug: Ozanimod
Drug: Interferon beta-1a placebo
Drug: Interferon beta-1a

First Posted Date: 2014-01-28

Last Posted Date: 2021-02-11

Lead Sponsor: Celgene

Target Recruit Count: 1320

Registration Number: NCT02047734

Locations: 🇺🇸
Neurostudies Inc, Port Charlotte, Florida, United States
🇵🇱
RESMEDICA Spolka z o.o., Kielce, Poland
🇵🇱
Receptos Study Site 402, Olsztyn, Poland

and more 296 locations

Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Pomalidomide and Dexamethasone

First Posted Date: 2014-01-24

Last Posted Date: 2021-08-27

Lead Sponsor: Celgene

Target Recruit Count: 81

Registration Number: NCT02045017

Locations: 🇮🇹
Arcispedale Santa Maria Nuova, Reggio Emilia, Italy
🇬🇧
Oxford Radcliffe Hospital ICRF Medical Oncology Unit, Headington, United Kingdom
🇫🇷
CHU de Poitiers, Poitiers, France

and more 19 locations

3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 Capsule

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: CC-220
Drug: Placebo

First Posted Date: 2014-01-13

Last Posted Date: 2014-01-13

Lead Sponsor: Celgene Corporation

Target Recruit Count: 64

Registration Number: NCT02034773

Locations: 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States

Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma

Phase 1

Terminated

Conditions: Lymphoma, Large B-Cell, Diffuse

Interventions: Drug: CC-122
Drug: CC-223
Drug: CC-292
Drug: Rituximab

First Posted Date: 2014-01-09

Last Posted Date: 2024-01-18

Lead Sponsor: Celgene

Target Recruit Count: 174

Registration Number: NCT02031419

Locations: 🇮🇹
Local Institution - 201, Turin, Italy
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Stanford Cancer Center, Stanford, California, United States

and more 13 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy